50% y-o-y organic sales growth in Q2'25e EBIT forecasts raised by 1.0-55.7% for '25e-'27e Q2'25 results due 19 August
ANNONS
Q2'25 expectations
We expect the positive sales momentum to have continued for OssDsign in Q2, driven by continued improved market access by adding new hospitals and deeper penetration among existing hospitals by broadening the base of surgeons using Catalyst. All in all, we forecast Q2 sales of SEK 41.8m, equal to organic growth of 50% y-o-y, and EBIT of SEK -8.6m on fairly flattish opex assumptions compared with Q1'25. Given its 100% sales exposure to the US and the USD, we estimate the FX headwind to have been 10% for Q2, holding back reported sales growth but also helping to keep the opex level relatively flattish compared with Q1'25 given the high cost base in USD. For Q2, we forecast a gross margin of 95.0%, down from 96.4% in Q1'25, partly due to the US tariffs.
